Safety, tolerability and clinical implementation of ‘ready-to-use’ 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
Sign Up to like & getrecommendations! Published in 2020 at "ESMO Open"
DOI: 10.1136/esmoopen-2019-000650
Abstract: Background 68Ga-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) positron emission tomography–CT (PET-CT) has superior diagnostic performance compared to the licensed tracer OctreoScan single photon emission CT–CT in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). A new preparation of 68Ga-DOTATOC using a… read more here.
Keywords: 68ga dotatoc; somakit toc; dotatoc somakit;